$AXGN News

Axogen: The Regulatory Moat Is Becoming A Commercial Flywheel

Canaccord Genuity Maintains Buy on Axogen, Raises Price Target to $55

Citizens Maintains Market Outperform on Axogen, Raises Price Target to $55

HC Wainwright & Co. Maintains Buy on Axogen, Raises Price Target to $53

Axogen, Inc. (AXGN) Q2 2026 Earnings Call Transcript

Axogen (NASDAQ:AXGN) Shares Slide After Q2 Earnings Miss Overshadows Revenue Beat and Raised Guidance

Axogen, Inc. 2026 Q2 - Results - Earnings Call Presentation

Axogen Q2 Adj. EPS $0.12 Misses $0.13 Estimate, Sales $69.731M Beat $67.098M Estimate

Axogen FY2026 Revenue expected to be at least $279.000M vs $270.882M Est

Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026

Axogen Inc. (NASDAQ:AXGN) Achieves a Perfect Technical Score and Strong Fundamental Growth

AxoGen, Stock Of The Day, Offers Entry After Bullish Rebound

AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam

Axogen, Inc. (AXGN) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

Axogen, Inc. (NASDAQ:AXGN) Analysts Are Pretty Bullish On The Stock After Recent Results

Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference

Citizens Maintains Market Outperform on Axogen, Raises Price Target to $50

Wells Fargo Maintains Overweight on Axogen, Raises Price Target to $48

HC Wainwright & Co. Maintains Buy on Axogen, Raises Price Target to $50

Axogen Inc (AXGN) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid Rising Expenses